ProQR Therapeutics’ (PRQR) “Buy” Rating Reiterated at Chardan Capital

ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $4.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s target price would indicate a potential upside of 54.44% from the stock’s previous close.

PRQR has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Zacks Research lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 15th. Finally, Evercore ISI reiterated an “outperform” rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.14.

ProQR Therapeutics Stock Down 5.8%

PRQR stock opened at $2.59 on Tuesday. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.21. The business’s fifty day moving average is $2.40 and its 200-day moving average is $2.09. The company has a market cap of $272.49 million, a P/E ratio of -5.63 and a beta of 0.16.

ProQR Therapeutics (NASDAQ:PRQR) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. The company had revenue of $4.33 million during the quarter, compared to analyst estimates of $5.01 million. Research analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently bought and sold shares of PRQR. Aberdeen Group plc acquired a new stake in shares of ProQR Therapeutics during the first quarter worth $2,461,000. Affinity Asset Advisors LLC raised its holdings in shares of ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after acquiring an additional 459,512 shares during the period. Monaco Asset Management SAM raised its holdings in shares of ProQR Therapeutics by 59.1% during the first quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company’s stock worth $628,000 after acquiring an additional 175,290 shares during the period. Jane Street Group LLC raised its stake in shares of ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the period. Finally, Walleye Capital LLC raised its stake in shares of ProQR Therapeutics by 11.6% in the 1st quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 52,261 shares during the period. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).